Providing a diverse range of perspectives from bullish to bearish, 3 analysts have published ratings on Arcturus Therapeutics (NASDAQ:ARCT) in the last three months.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 2 | 1 | 0 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 1 | 1 | 0 | 0 | 0 |
3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Arcturus Therapeutics, revealing an average target of $65.33, a high estimate of $70.00, and a low estimate of $63.00. This current average reflects an increase of 6.23% from the previous average price target of $61.50.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Arcturus Therapeutics is...
Comment(0)
Reason For Report